Cadonilimab with chemotherapy for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of cadonilimab (an immune-boosting drug) plus chemotherapy for locally advanced cervical cancer that hasn't been treated before. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Cervical cancer that is locally advanced (FIGO stage IB3, IIA2, IIB, or IIIC1r) and larger than 4 cm
- Confirmed diagnosis of squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma (specific types of cervical cancer)
- Age 18–75 years old
- Good overall health and able to have surgery to remove the uterus (radical hysterectomy) with intent to cure
- Not pregnant and willing to use contraception during the study
- No prior immunotherapy or other advanced cancer treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called cadonilimab for women with cervical cancer that has returned, spread, or is advanced. The goal is to see if it works well, how safe it is, and if it costs less than standard treatments.
This trial tests whether adding an immunotherapy drug called Cadonilimab (AK104) to standard chemoradiation can help people with locally advanced cervical cancer that has not spread to distant organs. The goal is to improve treatment outcomes for those who cannot have surgery.
This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.
This Phase 2 trial tests cadonilimab (an immunotherapy) combined with nab-paclitaxel (chemo) to treat cervical cancer that has come back or spread and did not respond to prior immune checkpoint medicines. It may help shrink tumors and improve disease control after prior immunotherapy failure.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.